Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients|[rsquo]| survival
jun ren,wenyuan li,liying yan,W Jiao,shuo tian,dong li,yuanping tang,genda gu,hong liu,zhen xu
DOI: https://doi.org/10.1038/bjc.2011.492
IF: 9.075
2011-01-01
British Journal of Cancer
Abstract:Renal cell carcinoma (RCC) is the most common carcinoma of the adult kidney, and its incidence has gradually increased during the last decades (Eble et al, 2004). Resection of the diseased kidney is a standard therapeutic approach for RCC. However, ~30% of patients develop metastatic disease after surgery (Zisman et al, 2002), and median survival of those patients is only about 13 months (Cohen and McGovern, 2005). The driving factors underlying RCC metastasis remain poorly defined and better understanding of RCC metastasis mechanisms is required for the development of rational strategies for the prevention and treatment of RCC recurrence. Cancerous inhibitor of protein phosphatase 2A (CIP2A), a cellular protein phosphatase 2A (PP2A) inhibitor, promotes the stability of c-Myc protein by inducing c-Myc serine 62 (S62) phosphorylation and inhibiting its degradation mediated by PP2A (Junttila et al, 2007). Experimentally identified as an oncoprotein, CIP2A contributes to immortalisation and malignant transformation of human cells. Importantly, recent studies show that CIP2A is over-expressed in various human malignancies including head and neck squamous cell carcinoma (Junttila et al, 2007), oral squamous cell carcinoma (Basile and Czerninski, 2010), oesophageal squamous cell carcinoma (Qu et al, 2010), colon (Junttila et al, 2007), gastric (Li et al, 2008), breast (Come et al, 2009), prostate (Vaarala et al, 2010), tongue (Bockelman et al, 2011), lung (Dong et al, 2011; Ma et al, 2011), cervical cancer (Liu et al, 2011) and acute myeloid leukaemia (Wang et al, 2011). Cancerous inhibitor of protein phosphatase 2A has also been found to be a prognostic factor for patients with gastric cancer (Khanna et al, 2009), early-stage tongue cancer (Bockelman et al, 2011) and non-small cell lung cancer (Dong et al, 2011). Expression and biological function of CIP2A in RCC has so far not been investigated. In the present study, we determined CIP2A expression in RCC and explored the potential effects of CIP2A on RCC metastasis and patients’ survival. The slides were scored by two independent pathologists, who were blind to the data of the patients, according to the intensity and percentage of CIP2A staining. Cancerous inhibitor of protein phosphatase 2A expression was scored as 0 (negative), 1 (mild, 0–4% positive cells), 2 (moderate, 5–49% positive cells) and 3 (strong, 50% positive cells). We further analysed CIP2A protein level in 107 RCC tissues, 19 tumour adjacent tissues and 6 normal renal tissues using an immunohistochemical approach. Consistent with CIP2A mRNA expression profile, the presence of the CIP2A protein was found in 75 of 107 (70%) of cancer samples, whereas only 6 of 19 (32%) tumour adjacent tissues and 1 of 6 (17%) normal renal tissues exhibited weak or diffuse CIP2A expression (P<0.0001). Cancerous inhibitor of protein phosphatase 2A staining was mainly observed in the cytoplasm and occasionally found in the nucleus of tumour cells (Figure 2A–E). Only weak or diffuse CIP2A staining was observed in some renal tubules in normal renal tissues (Figure 2H). Furthermore, the CIP2A staining level significantly correlated with primary tumour stage, lymph node metastasis, distant metastasis, TNM stage and histological grade (all P<0.05). There was no significant association between CIP2A expression and patients’ gender and age (Table 1). Among clear cell RCC patients, univariate and multivariate analysis showed analogous results (Tables 2 and 3). Also, higher-CIP2A expression indicated poor prognosis (P<0.0001; Figure 3B) and high-CIP2A expression was a significantly independent prognostic factor for clear cell RCC patients (P=0.001; Table 3). We further examined whether cell proliferation capacity was altered in cells with transfection of CIP2A siRNA. However, it was found that CIP2A depletion did not have a measurable blocking effect on cell proliferation in colony formation assay (data not shown). The present study provides the first evidence that CIP2A over-expression widely occurs in RCCs and positively correlates with advanced disease stages and metastasis, and negatively affects patients’ OS. Consistent with these clinical findings, experiments on RCC cell lines demonstrate that CIP2A depletion significantly inhibits migration and invasion of these RCC cells in vitro. Collectively, these results indicate a critical role of CIP2A in driving disease progression and spread of RCCs. Previous studies have shown that aberrant expression of CIP2A is associated with progressive diseases in a number of other human malignancies including breast (Come et al, 2009), tongue (Bockelman et al, 2011), lung (Dong et al, 2011; Ma et al, 2011), gastric (Li et al, 2008), head and neck cancers (Junttila et al, 2007) and chronic myeloid leukaemia (Lucas et al, 2011). More recently, CIP2A expression has been found to be associated with synovial hyperplasia and invasive function of fibroblast-like synoviocytes in rheumatoid arthritis (Lee et al, 2011). It is currently unclear how CIP2A promotes tumour cell invasion and metastasis. Based on the role of CIP2A in stabilising and up-regulating the MYC oncoprotein, it is likely that MYC is involved in CIP2A-stimulated invasiveness of tumour cells. The MYC oncoprotein is capable of conferring a selective advantage on cancer cells by stimulating proliferation, cell survival, differentiation blockade, genetic instability and angiogenesis, all of which may contribute to metastasis (Baudino et al, 2002; von Rahden et al, 2006; Gordan et al, 2007; Guffei et al, 2007; Vaque et al, 2008). Furthermore, MYC is necessary for the invasion and metastasis of cancer cells in experimental xenografts independent of its effects on proliferation and survival (Wolfer et al, 2010). More recently, MYC has been found to regulate the epithelial-to-mesenchymal transition, a required cellular programme for invasion and migration. MYC achieves this by stimulating TGF-β-mediated activation of the SNAIL transcription factor through a microRNA network involving the LIN28B/let-7/HMGA2 pathway (Smith et al, 2009; Viswanathan et al, 2009; Khew-Goodall and Goodall, 2010; Ma et al, 2010; Helland et al, 2011). All these effects of MYC may contribute to tumour cell metastasis driven by CIP2A, and further study is required to elucidate the role of MYC in CIP2A-mediated RCC metastasis. In some types of tumour cells, CIP2A depletion leads to impaired proliferation potential largely due to diminished MYC expression (Li et al, 2008; Come et al, 2009; Dong et al, 2011). However, neither A498 nor KRC/Y cells exhibited significant alterations in colony formation after CIP2A was knocked down. Clearly, CIP2A inhibition-mediated attenuation of RCC cell invasion is independent of cellular proliferation. This suggests that other factors may be involved in CIP2A promotion of RCC metastasis in addition to MYC. Cancer metastasis can be one of the key factors affecting patients’ survival, but other elements may also lead to poor survival. Recent studies demonstrate that CIP2A displays many other activities, for instance, promoting stem cell self-renewal and giving cancer cells resistance to chemotherapeutic agents (Chen et al, 2010; Kerosuo et al, 2010; Choi et al, 2011). Increased self-renewal of cancer stem cells and drug resistance may lead to treatment failure, and thereby poor outcomes for patients. Moreover, CIP2A was also implicated in the blockade of cellular senescence and differentiation, as shown in our previous study (Li et al, 2008). Therefore, different mechanisms result in unfavourable prognosis in RCC patients with CIP2A over-expression. Little is known about the mechanism underlying the aberrant expression of CIP2A in malignant cells. In gastric cancer, Helicobacter pylori infection up-regulates CIP2A expression through the Src and ERK pathways (Zhao et al, 2010). Cancerous inhibitor of protein phosphatase 2A is up-regulated by human papillomavirus 16 E7 oncoprotein in cervical cancer (Liu et al, 2011). In addition, CIP2A and MYC form a positive feedback regulation loop to affect each other's expression (Khanna et al, 2009). It is currently unclear what contributes to CIP2A over-expression in RCCs. In the present study, it was found that clear cell RCC exhibited enhanced CIP2A expression at a higher frequency. It is well established that VHL mutation and subsequent HIF1/2 α dysregulation play a key part in the pathogenesis of clear cell RCC (Krieg et al, 2000; Krishnamachary et al, 2006); therefore, it may be interesting to probe the effects of these molecular events on CIP2A expression. Also, differences in CIP2A distribution between normal renal tissues and RCC tissues were noticed, and the nuclear accumulation of CIP2A was occasionally seen in RCC tissues. Based on the above observations, dysregulation of CIP2A may occur at different levels in RCCs. In conclusion, it was found that CIP2A is over-expressed in RCCs especially in clear cell RCC and plays an important role in RCC metastasis. Higher expression of CIP2A positively correlates with the aggressive phenotype of RCCs, and predicts poor outcome of patients. Therefore, CIP2A may be a novel target for prevention and treatment of RCC metastasis and recurrence. This work was financially supported by the Natural Science Foundation of Shandong (No. 2010ZRE27284), Science and Technology Development Planning Foundation of Shandong (No. Y2003C10), National Natural Science Foundation of China (No. 81000868), Science Foundation for outstanding young scientists of Shandong Province (No. BS2009SW025) and Science Foundation of Ministry of Education of China (No. 20090131120057). We thank Dr Edward C Mignot, formerly professor of English at Shandong University, for linguistic advice.